The Health Resources and Services Administration (HRSA), Operation Warp Speed, and the Food and Drug Administration (FDA) will host a webinar to share information about preparing your health center to administer outpatient COVID-19 monoclonal antibodies (mAbs). What does readiness entail? What staff do I need? How many patients can I serve? Which patients can benefit from mAb? Does our insurance cover this practice? Speakers will answer these and other questions. Speakers from health centers that are already providing infusion therapy, as well as HRSA leadership, will be featured.
Tuesday, December 22
1:00-2:00 p.m. ET
Eli Lilly and Regeneron both received emergency use authorizations (EUA) from FDA for COVID-19 monoclonal antibodies (mAbs) indicated for at-risk patients with mild to moderate symptoms to reduce disease progression and hopefully prevent hospitalizations. Eli Lilly’s product (bamlanivimab) is a single mAb therapy. Regeneron’s product (casirivimab and imdevimab) is a therapy consisting of two mAbs that must be administered as a single infusion. The Department of Health and Human Services (HHS) is currently allocating both treatments to states/jurisdictions on a weekly basis.
To learn more about how you can prepare your health center for outpatient administration of these products, join this webinar and see the Operation Warp Speed Therapeutics Monoclonal Antibodies Playbook.